Acid-related disorders and use of antisecretory medication

Danish Medical Bulletin

Volumn 54, Issue 1, 2007, Pages 18-30

  Lassen, Annemarie Touborg ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIULCER AGENT; BISMUTH; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; STOMACH SECRETION INHIBITOR; TETRACYCLINE; TINIDAZOLE; ENZYME INHIBITOR; OMEPRAZOLE; PROTON PUMP; RANITIDINE;

ARTICLE; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; DRUG USE; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; FOLLOW UP; HEALTH SURVEY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LONG TERM CARE; PEPTIC ULCER; PRESCRIPTION; PRIMARY MEDICAL CARE; PROGNOSIS; RISK FACTOR; STOMACH CANCER; CONTROLLED CLINICAL TRIAL; DENMARK; DRUG ANTAGONISM; DRUG UTILIZATION; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HOSPITALIZATION; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; DENMARK; DRUG UTILIZATION; ENZYME INHIBITORS; ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HUMANS; MALE; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; RANITIDINE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33947715066     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. Lægemiddelstatistik 1998-2002 Danmark. 2003. Lægemiddelstyrelsen, København. Ref. Type: Serial (Book, Monograph).
2. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998;317(7156):452-6.
3. Martin RM, Lim AG, Kerry SM et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol. Ther 1998;12(8):797-805.
4. McManus P, Marley J, Birkett DJ et al. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. Br J Clin Pharmacol 1998;46(4):409-11.
5. Marshall JK, Grootendorst PV, O'Brien BJ et al. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 2002;166(13): 1655-62.
6. Westbrook JI, Duggan AE, McIntosh JH. Prescriptions for antiulcer drugs in Australia: volume, trends, and costs. BMJ 2001;323(7325): 1338-9.
7. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001;23(3):116-7.
8. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25(5):333-40.
9. Lægemiddelkataloget 2002. Copenhagen: Dansk Lægemiddelinformation A/S. 2002.
10. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. 1. N Engl J Med 1990;323(24):1672-80.
11. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases (2). N Engl J Med 1990;323(25):1749-55.
12. Maton PN. Omeprazole. N Engl J Med 1991;324(14):965-75.
13. Lockhart SP. Clinical review of lansoprazole. Br J Clin Pract Suppl 1994;75:48-55.
14. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001;61(15):2327-56.
15. van PB, Numans ME, Bonis PA et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004;(4):CD002095.
16. Lind T, Megraud F, Unge P et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116(2):248-53.
17. Laheij RJ, Rossum LG, Jansen JB et al. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment. Pharmacol Ther 1999;13(7):857-64.
18. Misiewicz JJ, Harris AW, Bardhan KD et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997;41(6):735-9.
19. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120(3):594-606.
20. Moayyedi P, Soo S, Deeks J et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003;(1):CD001960.
21. Moayyedi P, Delaney BC, Vakil N et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127(5):1329-37.
22. Talley NJ, Zinsmeister AR, Schleck CD et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102(4 Pt 1):1259-68.
23. Kay L, Jorgensen T. Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol 1994;29(1):2-6.
24. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ 1989;298(6665):30-2.
25. Jones RH, Lydeard SE, Hobbs FD et al. Dyspepsia in England and Scotland. Gut 1990;31(4):401-5.
26. Agreus L, Svardsudd K, Nyren O et al. The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol 1994;29(2):102-9.
27. Dominitz JA, Provenzale D. Prevalence of dyspepsia, heartburn, and peptic ulcer disease in veterans. Am J Gastroenterol 1999;94(8):2086-93.
28. Wildner-Christensen M, Moller HJ, Schaffalitzky de Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003;125(2):372-9.
29. Westbrook JI, McIntosh JH, Talley N. The impact of dyspepsia definition on prevalence estimates: Considerations for future researchers. Scand J Gastroenterol 2000;35:227-33.
30. Heikkinen M, Pikkarainen P, Takala J et al. General practitioners' approach to dyspepsia. Survey of consultation frequencies, treatment, and investigations. Scand J Gastroenterol 1996;31(7):648-53.
31. Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 2002;20(5):347-55.
32. Levin TR, Schmittdiel JA, Kunz K et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997;103(6):520-8.
33. Talley NJ, Silverstein MD, Agreus L et al. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998;114(3):582-95.
34. Malfertheiner P, Megraud F, O'morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16(2):167-80.
35. Delaney BC, Wilson S, Roalfe A et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet 2000;356(9246):1965-9.
36. Delaney B, Ford A, Forman D et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2005;(4):CD001961.
37. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barret's esophagus, and esophageal cancer: scientific review. JAMA 2002;287(15): 1972-81.
38. Shaheen N, Provenzale D. The epidemiology of gastroesophageal reflux disease. Am J Med Sci 2003;326(5):264-73.
39. Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. Am J Gastroenterol 2001;96(Suppl 8): S16-S18.
40. Talley NJ. Review article: gastro-oesophageal reflux disease - how wide is its span? Aliment Pharmacol Ther 2004:20 Suppl 5:27-37.
41. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 1995:27(1): 67-70.
42. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14(12):1589-94.
43. Locke GR, III, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112(5):1448-56.
44. az-Rubio M, Moreno-Elola-Olaso C, Rey E et al. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther 2004;19(1):95-105.
45. Dent J, el-Serag HB, Wallander MA et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54(5):710-7.
46. el-Serag HB, Petersen NJ, Carter J et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004; 126(7):1692-9.
47. Wildner-Christensen M, Hansen JM, Schaffalitzky-De MO. Prevalence and Risk Factors for Gastro-oesophageal Reflux Symptoms (GORS) in a Danish Population - Quality of Life and Use of Health Care Resources. Gastroenterology 2004;126(4 suppl 2):A-327.
48. Schoon IM, Mellstrom D, Oden A et al. Incidence of peptic ulcer disease in Gothenburg, 1985 [published erratum appears in BMJ 1990 Oct 20;301(6757):906]. BMJ 1989;299(6708):1131-4.
49. Ostensen H, Gudmundsen TE, Bolz KD et al. The incidence of gastric ulcer and duodenal ulcer in north Norway. A prospective epidemiological study. Scand J Gastroenterol 1985;20(2):189-92.
50. Kurata JH, Honda GD, Frankl H. The incidence of duodenal and gastric ulcers in a large health maintenance organization. Am J Public Health 1985;75(6):625-9.
51. Everhart JE, Byrd HD, Sonnenberg A. Incidence and risk factors for self-reported peptic ulcer disease in the United States. Am J Epidemiol 1998; 147(6):529-36.
52. Kurata JH, Nogawa AN, Abbey DE et al. A prospective study of risk for peptic ulcer disease in Seventh-Day Adventists. Gastroenterology 1992; 102(3):902-9.
53. Kang JY, Tinto A, Higham J et al. Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management. Aliment Pharmacol Ther 2002;16(6):1067-74.
54. Penston JG, Crombie IK, Waugh NR et al. Trends in morbidity and mortality from peptic ulcer disease: Tayside versus Scotland. Aliment Pharmacol Ther 1993;7(4):429-42.
55. Ohmann C, Thon K, Hengels KJ et al. Incidence and pattern of peptic ulcer bleeding in a defined geographical area. DUSUK Study Group. Scand J Gastroenterol 1992;27(7):571-81.
56. Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health 1996;86(2):200-5.
57. Munnangi S, Sonnenberg A. Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Intern Med 1997;157(13):1489-94.
58. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002;50(4):460-4.
59. Lewis JD, Bilker WB, Brensinger C et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002;97(10):2540-9.
60. Perez-Aisa MA, Del PD, Siles M et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;21(1):65-72.
61. Rosenstock S, Jorgensen T, Bonnevie O et al. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut 2003;52(2):186-93.
62. Rosenstock SJ, Jorgensen T. Prevalence and incidence of peptic ulcer disease in a Danish County - a prospective cohort study. Gut 1995; 36(6):819-24.
63. Andersen IB, Bonnevie O, Jorgensen T et al. Time trends for peptic ulcer disease in Denmark, 1981-1993. Analysis of hospitalization register and mortality data. Scand J Gastroenterol 1998;33(3):260-6.
64. van Leerdam ME, Vreeburg EM, Rauws EA et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003;98(7):1494-9.
65. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004;159(1):23-31.
66. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002;55(2):157-63.
67. Krol N, Spies T, van Balen J et al. Management of dyspepsia in general practice: an observational study. Quality in Primary Care 2003;(11): 173-80.
68. Quartero AO, Numans ME, Post MW et al. One-year prognosis of primary care dyspepsia: predictive value of symptom pattern, Helicobacter pylori and GP management. Eur J Gastroenterol Hepatol 2002; 14(1):55-60.
69. Panter SJ, O'Flanagan H, Bramble MG et al. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome. Aliment Pharmacol Ther 2004; 19(9):981-8.
70. Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000;46(4):464-7.
71. Farrow DC, Vaughan TL, Sweeney C et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11(3):231-8.
72. Wayman J, Hayes N, Griffin SM. The response of early gastric cancer to proton-pump inhibitors. N Engl J Med 1998;338(26):1924-5.
73. Wayman J, Hayes N, Raimes SA et al. Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 2000;9(4):385-8.
74. Csendes A, Smok G, Burdiles P et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus 2000;13(1):5-11.
75. Winters C Jr, Spurling TJ, Chobanian SJ et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92(1):118-24.
76. Corder AP, Jones RH, Sadler GH et al. Heartburn, oesophagitis and Barrett's oesophagus in self-medicating patients in general practice. Br J Clin Pract 1996;50(5):245-8.
77. Cameron AJ, Zinsmeister AR, Ballard DJ et al. Prevalence of columnarlined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99(4):918-22.
78. Shaheen NJ, Crosby MA, Bozymski EM et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119(2):333-8.
79. Murray L, Watson P, Johnston B et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003;327(7414):534-5.
80. Hage M, Siersema PD, van DH et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004;39(12):1175-9.
81. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340(11):825-31.
82. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003; 98(5):940-8.
83. Chow WH, Finkle WD, McLaughlin JK et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274(6):474-7.
84. Ye W, Chow WH, Lagergren J et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001;121(6):1286-93.
85. Lagergren J. Oesophageal cancer and gastro-oesophageal reflux: what is the relationship? Gut 2004;53(8):1064-5.
86. Frank L. Epidemiology. When an entire country is a cohort. Science 2000;287(5462):2398-9.
87. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44(4):445-8.
88. Classification index including Defined Daily Doses (DDD) for plain substances. WHO collaborating center for drug statistical methodology 1995.
89. Andersen TF, Madsen M, Jorgensen J et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46(3):263-8.
90. Storm HH, Michelsen EV, Clemmensen IH et al. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997;44(5): 535-9.
91. Ryder SD, O'Reilly S, Miller RJ et al. Long term acid suppressing treatment in general practice. BMJ 1994;308(6932):827-30.
92. Boutet R, Wilcock M, MacKenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 1999;13(6):813-7.
93. Goudie BM, McKenzie PE, Cipriano J et al. Repeat prescribing of ulcer healing drugs in general practice - prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996;10(2):147-50.
94. Hungin AP, Rubin GF, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49(443):451-3.
95. Rubin GP, Contractor B, Bramble MG. The use of long-term acid-suppression therapy. Br J Clin Pract 1995;49(3):119-20.
96. Hurenkamp GJ, Grundmeyer HG, Bindels PJ et al. How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices. J Fam Pract 2002;51(3):241-5.
97. Jacobson BC, Ferris TG, Shea TL et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003;98(1):51-8.
98. Majumdar SR, Soumerai SB, Farraye FA et al. Chronic acid-related-disorders are common and underinvestigated. Am J Gastroenterol 2003; 98(11):2409-14.
99. De Wit NJ, Quartero AO, Numans ME. Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case-finding in general practice. Aliment Pharmacol Ther 1999; 13(10):1317-21.
100. Verma S, Giaffer MH. Helicobacter pylori eradication ameliorates symptoms and improves quality of life in patients on long-term acid suppression. A large prospective study in primary care. Dig Dis Sci 2002;47(7):1567-74.
101. Quartero AO, Smeets HM, De Wit NJ. Trends and determinants of pharmacotherapy for dyspepsia: analysis of 3-year prescription data in The Netherlands. Scand J Gastroenterol 2003;38(6):676-7.
102. Roberts SJ, Bateman DN. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995;9(2):137-43.
103. Thors H, Sigurdsson H, Oddsson E et al. Survey of prescriptions for peptic ulcer drugs (ACT class AOB2) in Iceland. Scand J Gastroenterol 1994;29(11):988-94.
104. Cooper AL, Langworthy H, Porter S. Cost-effective prescribing of proton pump inhibitor therapy: an audit in general practice. Int J Clin Pract 2000;54(5):287-92.
105. McBride JE, Pater JL, Dorland JL et al. Extent and variation of omeprazole prescribing in an elderly population of Ontario. Ann Pharmacother 1997;31(4):411-6.
106. Schwartz LM, Woloshin S, Welch HG. Trends in diagnostic testing following a national guideline for evaluation of dyspepsia. Arch Intern Med 1996;156(8):873-5.
107. Scott BB. Gastroenterology in the Trent Region in 1992 and a review of changes since 1975. Gut 1995;36(3):468-72.
108. Westbrook JI, Rushworth RL, Rob MI et al. Diagnostic procedures and health outcomes. Upper gastrointestinal tract investigations in the elderly. Med J Aust 1993;159(4):242-5.
109. Westbrook JI. Trends in the utilization of diagnostic upper GI endoscopy in New South Wales, Australia, 1988 to 1998. Gastrointest Endosc 2002;55(7):847-53.
110. Loffeld RJ, van der Putten AB. The yield of UGIE: a study of a ten-year period in the "Zaanstreek". Neth J Med 2003;61(1):14-8.
111. Loffeld RJ, van der Putten AB. Rising incidence of reflux oesophagitis in patients undergoing upper gastrointestinal endoscopy. Digestion 2003; 68(2-3):141-4.
112. Bytzer P, Hansen JM, Havelund T et al. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol 1996;8(4):359-63.
113. Hungin AP, Thomas PR, Bramble MG et al. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract 1994;44(388):519-21.
114. Hansen JM, Bytzer P, Bondesen S et al. Efficacy and outcome of an open access endoscopy service. Dan Med Bull 1991;38(3):288-90.
115. Mitchell RM, Collins JS, Watson RG et al. Differences in the diagnostic yield of upper gastrointestinal endoscopy in dyspeptic patients receiving proton-pump inhibitors and H2-receptor antagonists. Endoscopy 2002;34(7):524-6.
116. Manes G, Balzano A, Marone P et al. Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines. Aliment Pharmacol Ther 2002;16(1):105-10.
117. Jones R. What happens to patients with non-ulcer dyspepsia after endoscopy? Practitioner 1988;232(1441):75-6,78.
118. McColl KE, Dickson A, El-Nujumi A et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95(1):101-5.
119. Kearney DI, Liu CF, Crunip C et al. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia. Am J Gastroenterol 2003;98(9):1952-62.
120. Forrest EH. MacKenzie JF, Stuart RC et al. Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting. Scott Med J 2002;47(2):28-33.
121. Tan AC, Hartog GD, Mulder CJ. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication. Aliment Pharmacol Ther 1999;13(11):1519-22.
122. Hurenkamp GJ, Grundmeijer HG, Van Der EA et al. Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study. Aliment Pharmacol Ther 2001;15(7):1047-54.
123. Khan Z, Nair P, O'Shea C et al. Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. Scand J Gastroenterol 2002;37(2):144-7.
124. Fendrick AM. Chey WD, Margaret N et al. Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Am J Med 1999;107(2):133-6.
125. Sonnenberg A, Schwartz JS, Cutler AF et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multi-center trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med 1998;158(8):852-60.
126. Powell KU, Bell GD. Bolton GH et al. Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications. Q J Med 1994;87(5):283-90.
127. Reilly TG, Ayres RC, Poxon V et al. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995;9(5):483-90.
128. Levin TR, Schmittdiel JA, Henning JM et al. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 1998;93(5):743-7.
129. de Boer WA, Tytgat GN. Search and treat strategy to eliminate Helicobacter pylori associated ulcer disease. Gut 2001;48(4):567-70.
130. Arents NL. Thijs JC, van Zwet AA et al. Approach to treatment of dyspepsia in primary care: a randomized trial comparing "test-and-treat" with prompt endoscopy. Arch Intern Med 2003;163(13):1606-12.
131. Laheij RJ, Van Rossum LG, Heinen N et al. Long-term follow-up of empirical treatment or prompt endoscopy for patients with persistent dyspeptic symptoms? Eur J Gastroenterol Hepatol 2004;16(8):785-9.
132. McColl KE, Murray LS, Gillen D et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ 2002; 324(7344):999-1002.
133. Heaney A, Collins JS, Watson RG et al. A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45(2):186-90.
134. Ford AC, Qume M, Moayyedi P et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128(7):1838-44.
135. Mantynen T, Farkkila M, Kunnamo I et al. The Impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants. Am J Gastroenterol 2002;97(10):2524-9.
136. Aro PT, Ronkainen JA, Storskrubb T et al. Findings at upper endoscopy in a random adult population. A report from the Kalixanda study. Gastroenterology 2002;122(suppl):A-568.
137. Akdamar K, Ertan A, Agrawal NM et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc 1986; 32(2):78-80.
138. Voutilainen M, Sipponen P, Mecklin JP et al. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000;61(1):6-13.
139. el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998;43(3):327-33.
140. Ho KY, Chan YH, Kang JY. Increasing trend of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country. Am J Gastroenterol 2005;100(9):1923-8.
141. Bonnevie O. The incidence of duodenal ulcer in Copenhagen County. Scand J Gastroenterol 1975;10(4):385-93.
142. Bonnevie O. The incidence of gastric ulcer in Copenhagen county. Scand J Gastroenterol 1975;10(3):231-9.
143. Garcia Rodriguez LA, Ruigomez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology 1999;10(3): 228-32.
144. Gutthann SP. Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8(1):18-24.
145. Garcia Rodriguez LA, Ruigomez A, Hasselgren G et al. Comparison of mortality from peptic ulcer bleed between patients with or without peptic ulcer antecedents. Epidemiology 1998;9(4):452-6.
146. Rorbaek-Madsen M, Fischer L, Thomsen H et al. Late outcome of bleeding gastric ulcer. Five to eight years' follow-up. Scand J Gastroenterol 1994;29(11):983-7.
147. Hung LC, Ching JY, Sung JJ et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005;128(7):1845-50.
148. Lanas A, Perez-Aisa MA, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100(8):1685-93.
149. Lee S, Lida M, Yao T et al. Long-term follow-up of 2529 patients with gastric and duodenal ulcer: survival rate and causes of death. Gastroenterology 1988;94(2):381-6.
150. Xia HH, Phung N, Altiparmak E et al. Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998. Dig Dis Sci 2001;46(12):2716-23.
151. Solaymani-Dodaran M, Logan RE West J et al. Risk of oesophageal cancer in Barretts oesophagus and gastro-oesophageal reflux. Gut 2004; 53(8):1070-4.
152. Andrade SE, Gurwitz JH, Chan KA et al. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol 2002;55(3): 310-3.
153. Allison JE, Hurley LB, Hiatt RA et al. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med 2003;163(10):1165-71.
154. Raiford DS, Perez GS, Garcia RL. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996; 7(1):101-4.
155. Cattaruzzi C, Troncon MG, Agostinis L et al. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol 1999;52(6):499-502.
156. Lau HS, de-Boer A, Beuning KS et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50(5):619-25.
157. West SL, Savitz DA, Koch G et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142(10):1103-12.
158. Tamblyn R, Lavoie G, Petrella L et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48(8):999-1009.
159. Juul KV, Thomsen OO, Nissen A et al. National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions. Scand J Gastroenterol 1998;33(9):928-32.
160. Foy R, Parry J, Duggan A et al. How evidence based are recruitment strategies to randomized controlled trials in primary care? Experience from seven studies. Fam Pract 2003;20(1):93-92.
161. Jarbol D, Kragstrup, J, Havelund T, and Schaffalitzky de Muckadell OB. Efficacy of three strategies based on empitical antisecretory therapy and Helicobacter pylori status - for management of dyspepsia in general practice. A randomized controlled trial. Gastroenterology 2005;124 (Suppl 2):A-69 (Abstract).
162. Duggan AE, Elliott C, Tolley K et al. Randomized controlled trial of four dyspepsia management strategies in primary care with 12 month follow-up. Gastroenterology 2000;118:A438.
163. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Eng J Med 2005; 352(3):238-44.